PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26221F0077Jynarque tolvaptan pharmaceutical — Otsuka America Pharmaceutical, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Nov 23, 2021 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

262-Network Contract Office 22 (36C262)

Awarding office

Otsuka America Pharmaceutical, Inc

Recipient

Nov 23, 2021

PoP end

$-8,357.51

Obligated

$103K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Otsuka America Pharmaceutical, Inc — $90

Contract facts

Federal

Contract number36C26221F0077

Also listed as36C262-21-F-0077

Also listed as36F79720D0099-36C26221F0077

Agency262-Network Contract Office 22 (36C262)

Awarding office262-Network Contract Office 22 (36C262)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentOtsuka America Pharmaceutical, Inc

CAGE0ZHV7

UEIQKABLBMA8FT9

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79720D0099

Place of performanceSAN DIEGO CA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startNov 18, 2020

PoP end (current)Nov 23, 2021

Obligated$-8,357.51

Current value$103K

Potential value$103K

TOLVAPTAN (JYNARQUE) PHARMACEUTICAL is a federal award for 262-Network Contract Office 22 (36C262) held by Otsuka America Pharmaceutical, Inc. Estimated value $103K ($-8,357.51 obligated). Current period of performance ends Nov 23, 2021. Last award drew 1 bidder. Place of performance: SAN DIEGO CA.

Recompete timing

Public

● Past PoP end (1732 days ago)

Current PoP ended Nov 23, 2021 (1732 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26221F0077?

36C26221F0077 (Jynarque tolvaptan pharmaceutical) is a 262-Network Contract Office 22 (36C262) award with a potential value of $103K, currently held by Otsuka America Pharmaceutical, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C262-21-F-0077?

36C262-21-F-0077 is the dashed form of PIID 36C26221F0077 (Jynarque tolvaptan pharmaceutical), held by Otsuka America Pharmaceutical, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26221F0077?

262-Network Contract Office 22 (36C262) awarded 36C26221F0077 to Otsuka America Pharmaceutical, Inc (potential $103K).

Who is the incumbent on 36C26221F0077?

Otsuka America Pharmaceutical, Inc is the incumbent. The current period of performance ends Nov 23, 2021.

When does Otsuka America Pharmaceutical, Inc’s 36C26221F0077 come up for recompete?

SCOUT tracks a period-of-performance end of Nov 23, 2021. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Oct 1, 2022 · refreshed monthly